270 related articles for article (PubMed ID: 7677934)
1. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
[TBL] [Abstract][Full Text] [Related]
2. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.
Bajorin DF; Motzer RJ; Rodriguez E; Murphy B; Bosl GJ
J Natl Cancer Inst; 1993 Jan; 85(1):60-2. PubMed ID: 7677936
[No Abstract] [Full Text] [Related]
3. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.
Inoue Y; Nakamura T; Nakanishi H; Oishi M; Hongo F; Okihara K; Mizutani S; Kuroda J; Ukimura O
Int J Urol; 2018 Jul; 25(7):678-683. PubMed ID: 29752743
[TBL] [Abstract][Full Text] [Related]
4. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Wierecky J; Kollmannsberger C; Boehlke I; Kuczyk M; Schleicher J; Schleucher N; Metzner B; Kanz L; Hartmann JT; Bokemeyer C
J Cancer Res Clin Oncol; 2005 Apr; 131(4):255-60. PubMed ID: 15627215
[TBL] [Abstract][Full Text] [Related]
5. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
[TBL] [Abstract][Full Text] [Related]
6. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
[TBL] [Abstract][Full Text] [Related]
7. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
Schneider DT; Hilgenfeld E; Schwabe D; Behnisch W; Zoubek A; Wessalowski R; Göbel U
J Clin Oncol; 1999 Oct; 17(10):3226-33. PubMed ID: 10506623
[TBL] [Abstract][Full Text] [Related]
8. [A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy].
Kamai T; Touma T; Masuda H; Hyouchi N; Okuno T; Yonese J; Fukuda H; Tachibana Y; Ishiwata D
Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):875-9. PubMed ID: 8691713
[TBL] [Abstract][Full Text] [Related]
9. Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour.
Bokemeyer C; Freund M; Schmoll HJ; Rieder H; Fonatsch C
Ann Oncol; 1992 Nov; 3(9):772. PubMed ID: 1280461
[No Abstract] [Full Text] [Related]
10. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
11. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
12. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
Pizzocaro G; Salvioni R; Piva L; Faustini M; Nicolai N; Gianni L
Ann Oncol; 1992 Mar; 3(3):211-6. PubMed ID: 1316779
[TBL] [Abstract][Full Text] [Related]
13. Secondary ANLL with t(11;19)(q23;p13) following etoposide and cisplatin for ovarian germ cell tumor.
Kapoor G; Kadam PR; Chougule A; Gladstone B; Advani SH
Indian J Cancer; 1997 Jun; 34(2):84-7. PubMed ID: 9491667
[TBL] [Abstract][Full Text] [Related]
14. [Secondary leukemia following ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer].
Matsumoto S; Matsuda H; Uejima S; Kurita T
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):687-91. PubMed ID: 11109821
[TBL] [Abstract][Full Text] [Related]
15. [A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
Takizawa A; Miura T; Fujinami K; Osada Y; Tanaka M; Maruta I
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):701-4. PubMed ID: 16363657
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
18. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
Pedersen-Bjergaard J; Daugaard G; Hansen SW; Philip P; Larsen SO; Rørth M
Lancet; 1991 Aug; 338(8763):359-63. PubMed ID: 1713639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
